Efficacy of a vaccine based on protective antigen and killed spores against experimental inhalational anthrax

Protective antigen (PA)-based anthrax vaccines acting on toxins are less effective than live attenuated vaccines, suggesting that additional antigens may contribute to protective immunity. Several reports indicate that capsule or spore-associated antigens may enhance the protection afforded by PA. A...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Infection and immunity Ročník 77; číslo 3; s. 1197
Hlavní autoři: Gauthier, Yves P, Tournier, Jean-Nicolas, Paucod, Jean-Charles, Corre, Jean-Philippe, Mock, Michèle, Goossens, Pierre L, Vidal, Dominique R
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 01.03.2009
Témata:
Administration, Inhalation
Administration, Intranasal
Animals
Anthrax - immunology
Anthrax - prevention & control
Anthrax Vaccines - administration & dosage
Anthrax Vaccines - immunology
Antibodies, Bacterial - blood
Antibodies, Bacterial - immunology
Antigens, Bacterial - administration & dosage
Antigens, Bacterial - immunology
Bacillus anthracis - immunology
Disease Models, Animal
Enzyme-Linked Immunosorbent Assay
Guinea Pigs
Injections, Subcutaneous
Lung Diseases - immunology
Lung Diseases - microbiology
Lung Diseases - prevention & control
Mice
Spores, Bacterial - immunology
ISSN:1098-5522, 1098-5522
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Protective antigen (PA)-based anthrax vaccines acting on toxins are less effective than live attenuated vaccines, suggesting that additional antigens may contribute to protective immunity. Several reports indicate that capsule or spore-associated antigens may enhance the protection afforded by PA. Addition of formaldehyde-inactivated spores (FIS) to PA (PA-FIS) elicits total protection against cutaneous anthrax. Nevertheless, vaccines that are effective against cutaneous anthrax may not be so against inhalational anthrax. The aim of this work was to optimize immunization with PA-FIS and to assess vaccine efficacy against inhalational anthrax. We assessed the immune response to recombinant anthrax PA from Bacillus anthracis (rPA)-FIS administered by various immunization protocols and the protection provided to mice and guinea pigs infected through the respiratory route with spores of a virulent strain of B. anthracis. Combined subcutaneous plus intranasal immunization of mice yielded a mucosal immunoglobulin G response to rPA that was more than 20 times higher than that in lung mucosal secretions after subcutaneous vaccination. The titers of toxin-neutralizing antibody and antispore antibody were also significantly higher: nine and eight times higher, respectively. The optimized immunization elicited total protection of mice intranasally infected with the virulent B. anthracis strain 17JB. Guinea pigs were fully protected, both against an intranasal challenge with 100 50% lethal doses (LD(50)) and against an aerosol with 75 LD(50) of spores of the highly virulent strain 9602. Conversely, immunization with PA alone did not elicit protection. These results demonstrate that the association of PA and spores is very much more effective than PA alone against experimental inhalational anthrax.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1098-5522
1098-5522
DOI:10.1128/IAI.01217-08